Control Bionics' (ASX:CBL) US business reported record revenue of nearly $1 million in the fiscal second quarter ended December 2024, according to a Jan. 31 filing with the Australian bourse.
Cash receipts surpassed AU$1.4 million, representing an almost 30% year-on-year rise on the back of strong US sales and improving National Disability and Insurance Scheme approvals, per the filing.
Elsewhere, the medical device company logged its first sales in the UK and Ireland following the Smart Box distribution agreement.
Control Bionics reported net cash outflows of AU$1.7 million for the fiscal Q2.
The company said it is "positioned for strong growth" in the second half of the fiscal year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.